Application of secretary luciferase labeled orthotopic transplant model of hepatocellular carcinoma to evaluate tumor response to interferon-beta gene therapy.
- Author:
Gang WANG
1
;
Zhonghui LIAN
;
Wenhong TIAN
;
Xiaoyan DONG
;
Jie YUCHI
;
Xiaobing WU
Author Information
1. Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Carcinoma, Hepatocellular;
pathology;
therapy;
Cell Line, Tumor;
Genes, Reporter;
Genetic Therapy;
Interferon-beta;
genetics;
therapeutic use;
Liver Neoplasms;
pathology;
therapy;
Luciferases;
blood;
genetics;
secretion;
Mice;
Mice, Inbred C57BL;
Neoplasm Transplantation;
Treatment Outcome
- From:
Chinese Journal of Biotechnology
2012;28(10):1236-1244
- CountryChina
- Language:Chinese
-
Abstract:
To establish an orthotopic transplant mouse model of hepatocellular carcinoma (HCC) labeled with secretary luciferase and to study its response to anti-tumor treatment with interferon-beta gene therapy. We labeled the murine hepatoma Hepal-6 cells with secretary Gaussia princeps luciferase (Gluc), and then injected Gluc labeled Hepal-6 cells intrasplenically in C57BL/6 mice. We monitored blood Glue to evaluate the tumor development and anti-tumor effects of hydrodynamic injection with interferon-beta expressing plasmid. We successfully established the orthotopic mouse model of HCC by intrasplenic injection of Glue labeled Hepal-6 cells. The Glue blood assay could reflect the amount of cancer cells in vivo, tumor progression, as well as anti-tumor effect of interferon-beta gene therapy. In conclusion, Gluc labeled orthotopic transplant mouse model of HCC can ex vivo real-time monitor the tumor development and tumor response to treatments.
